Shilpa Medicare’s Pemetrexed Injection 1000 mg/100 ml, 500 mg/50 ml & 100 mg/10 ml, Ready to use formulation is approved by European Authorities, through its agreed partners in Europe. The product will be manufactured, for EU commercialization at its own EU GMP compliant, injectable manufacturing facility situated in Telangana state.
Shilpa has developed Pemetrexed formulation as liquid/ ready to use injection, against lyophilized powder formulation of reference, ALIMTA.
Shilpa’s Pemetrexed Injection is a unique formulation, which is supplied as ready to use formulation without any further dilution. The product is stable at room temperature. Pemetrexed injection is used in the treatment of malignant pleural mesothelioma & non-small cell lung cancer.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: